Literature DB >> 30394734

H4octox: Versatile Bimodal Octadentate Acyclic Chelating Ligand for Medicinal Inorganic Chemistry.

Xiaozhu Wang1, María de Guadalupe Jaraquemada-Peláez1, Cristina Rodríguez-Rodríguez2,3, Yang Cao1, Christian Buchwalder4, Neha Choudhary1,5, Una Jermilova1,5, Caterina F Ramogida5,6, Katayoun Saatchi4, Urs O Häfeli4, Brian O Patrick1, Chris Orvig1.   

Abstract

H4octox, a versatile new octadentate acyclic chelating ligand, has been investigated as an alternative to the acyclic DTPA and the macrocyclic DOTA for trivalent metal ions useful in diagnostic medical imaging or therapeutic applications (Y3+, In3+, La3+, Gd3+, Lu3+). The synthesis of H4octox is straightforward in less steps and thus more economical than those of most previously reported chelators. Complex formation equilibria in the presence of Y3+, In3+, La3+, Gd3+, and Lu3+ revealed fast chelation and high metal-sequestering capacity. Quantitative labeling with 111In3+ was achieved within 15 min at room temperature at ligand concentrations as low as 10-7 M, exactly the properties required for the development of kit-based radiopharmaceuticals. In vitro serum stability studies and in vivo SPECT imaging confirmed excellent complex stability of [111In(octox)]-. Moreover, it is more lipophilic than most of the multidentate carboxylate- or picolinate-based chelators; it therefore shows more liver clearance and provides a complementary choice in the design of metal-based pharmaceuticals and in the tuning of their pharmacokinetic properties. Finally, H4octox showed a large fluorescence enhancement upon complexation with different metals, in particular, with Y3+ and Lu3+, which could be useful for non-radioactive fluorescent stability and cell studies as well as bimodal imaging. Excellent in vitro stability of [Y(octox)]- against transferrin and Fe3+ was confirmed employing this fluorescence.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30394734     DOI: 10.1021/jacs.8b09964

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  5 in total

Review 1.  The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

Authors:  Holis Abdul Holik; Faisal Maulana Ibrahim; Angela Alysia Elaine; Bernap Dwi Putra; Arifudin Achmad; Achmad Hussein Sundawa Kartamihardja
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

Review 2.  Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations.

Authors:  Ruslan G Tuguntaev; Abid Hussain; Chenxing Fu; Haoting Chen; Ying Tao; Yan Huang; Lu Liu; Xing-Jie Liang; Weisheng Guo
Journal:  J Nanobiotechnology       Date:  2022-05-19       Impact factor: 9.429

3.  [nat/44Sc(pypa)]-: Thermodynamic Stability, Radiolabeling, and Biodistribution of a Prostate-Specific-Membrane-Antigen-Targeting Conjugate.

Authors:  Lily Li; María de Guadalupe Jaraquemada-Peláez; Eduardo Aluicio-Sarduy; Xiaozhu Wang; Dawei Jiang; Meelad Sakheie; Hsiou-Ting Kuo; Todd E Barnhart; Weibo Cai; Valery Radchenko; Paul Schaffer; Kuo-Shyan Lin; Jonathan W Engle; François Bénard; Chris Orvig
Journal:  Inorg Chem       Date:  2020-01-24       Impact factor: 5.165

4.  Metal ion size profoundly affects H3glyox chelate chemistry.

Authors:  Neha Choudhary; Kendall E Barrett; Manja Kubeil; Valery Radchenko; Jonathan W Engle; Holger Stephan; María de Guadalupe Jaraquemada-Peláez; Chris Orvig
Journal:  RSC Adv       Date:  2021-04-27       Impact factor: 4.036

Review 5.  Dual-Labelling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives.

Authors:  Manja Kubeil; Irma Ivette Santana Martínez; Michael Bachmann; Klaus Kopka; Kellie L Tuck; Holger Stephan
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.